Logo image of IONS

IONIS PHARMACEUTICALS INC (IONS) Stock Fundamental Analysis

NASDAQ:IONS - US4622221004 - Common Stock

42.635 USD
+0.02 (+0.04%)
Last: 8/29/2025, 8:00:02 PM
42.635 USD
0 (0%)
After Hours: 8/29/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IONS. IONS was compared to 545 industry peers in the Biotechnology industry. IONS may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, IONS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year IONS has reported negative net income.
In the past year IONS has reported a negative cash flow from operations.
In the past 5 years IONS always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: IONS reported negative operating cash flow in multiple years.
IONS Yearly Net Income VS EBIT VS OCF VS FCFIONS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

1.2 Ratios

Looking at the Return On Assets, with a value of -8.99%, IONS belongs to the top of the industry, outperforming 84.01% of the companies in the same industry.
The Return On Equity of IONS (-42.46%) is better than 69.67% of its industry peers.
Industry RankSector Rank
ROA -8.99%
ROE -42.46%
ROIC N/A
ROA(3y)-12.67%
ROA(5y)-11.54%
ROE(3y)-72.98%
ROE(5y)-56.49%
ROIC(3y)N/A
ROIC(5y)N/A
IONS Yearly ROA, ROE, ROICIONS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

1.3 Margins

IONS has a better Gross Margin (98.89%) than 97.61% of its industry peers.
In the last couple of years the Gross Margin of IONS has remained more or less at the same level.
IONS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.08%
GM growth 5Y-0.24%
IONS Yearly Profit, Operating, Gross MarginsIONS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

3

2. Health

2.1 Basic Checks

IONS does not have a ROIC to compare to the WACC, probably because it is not profitable.
IONS has more shares outstanding than it did 1 year ago.
IONS has more shares outstanding than it did 5 years ago.
The debt/assets ratio for IONS has been reduced compared to a year ago.
IONS Yearly Shares OutstandingIONS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
IONS Yearly Total Debt VS Total AssetsIONS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

IONS has an Altman-Z score of 1.36. This is a bad value and indicates that IONS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IONS (1.36) is better than 65.26% of its industry peers.
A Debt/Equity ratio of 0.99 indicates that IONS is somewhat dependend on debt financing.
IONS has a worse Debt to Equity ratio (0.99) than 76.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Altman-Z 1.36
ROIC/WACCN/A
WACC8.96%
IONS Yearly LT Debt VS Equity VS FCFIONS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

IONS has a Current Ratio of 2.87. This indicates that IONS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of IONS (2.87) is worse than 65.63% of its industry peers.
A Quick Ratio of 2.86 indicates that IONS has no problem at all paying its short term obligations.
IONS has a Quick ratio of 2.86. This is in the lower half of the industry: IONS underperforms 63.60% of its industry peers.
Industry RankSector Rank
Current Ratio 2.87
Quick Ratio 2.86
IONS Yearly Current Assets VS Current LiabilitesIONS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

5

3. Growth

3.1 Past

IONS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.98%, which is quite impressive.
Looking at the last year, IONS shows a quite strong growth in Revenue. The Revenue has grown by 16.05% in the last year.
IONS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.88% yearly.
EPS 1Y (TTM)26.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%255.56%
Revenue 1Y (TTM)16.05%
Revenue growth 3Y-4.54%
Revenue growth 5Y-8.88%
Sales Q2Q%100.67%

3.2 Future

The Earnings Per Share is expected to grow by 25.75% on average over the next years. This is a very strong growth
IONS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.04% yearly.
EPS Next Y15.47%
EPS Next 2Y1.66%
EPS Next 3Y12.11%
EPS Next 5Y25.75%
Revenue Next Year38.9%
Revenue Next 2Y22.13%
Revenue Next 3Y25.89%
Revenue Next 5Y29.04%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IONS Yearly Revenue VS EstimatesIONS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
IONS Yearly EPS VS EstimatesIONS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IONS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IONS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IONS Price Earnings VS Forward Price EarningsIONS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IONS Per share dataIONS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as IONS's earnings are expected to grow with 12.11% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.66%
EPS Next 3Y12.11%

More info and screens

0

5. Dividend

5.1 Amount

IONS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IONIS PHARMACEUTICALS INC

NASDAQ:IONS (8/29/2025, 8:00:02 PM)

After market: 42.635 0 (0%)

42.635

+0.02 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2025-07-30/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners106.71%
Inst Owner Change-0.29%
Ins Owners0.77%
Ins Owner Change2.49%
Market Cap6.80B
Analysts81.21
Price Target60.31 (41.46%)
Short Float %7.46%
Short Ratio5.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)138.96%
Min EPS beat(2)18.36%
Max EPS beat(2)259.57%
EPS beat(4)4
Avg EPS beat(4)84.95%
Min EPS beat(4)18.36%
Max EPS beat(4)259.57%
EPS beat(8)8
Avg EPS beat(8)62.05%
EPS beat(12)11
Avg EPS beat(12)45.8%
EPS beat(16)13
Avg EPS beat(16)59.56%
Revenue beat(2)2
Avg Revenue beat(2)26.69%
Min Revenue beat(2)3.26%
Max Revenue beat(2)50.13%
Revenue beat(4)4
Avg Revenue beat(4)29.02%
Min Revenue beat(4)0.96%
Max Revenue beat(4)61.73%
Revenue beat(8)7
Avg Revenue beat(8)29.7%
Revenue beat(12)10
Avg Revenue beat(12)22.78%
Revenue beat(16)12
Avg Revenue beat(16)20.42%
PT rev (1m)2.68%
PT rev (3m)2.11%
EPS NQ rev (1m)-22.6%
EPS NQ rev (3m)-31.56%
EPS NY rev (1m)18.32%
EPS NY rev (3m)20.64%
Revenue NQ rev (1m)-4.93%
Revenue NQ rev (3m)-24.52%
Revenue NY rev (1m)13.83%
Revenue NY rev (3m)16.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.2
P/FCF N/A
P/OCF N/A
P/B 10.76
P/tB 10.76
EV/EBITDA N/A
EPS(TTM)-1.84
EYN/A
EPS(NY)-2.94
Fwd EYN/A
FCF(TTM)-1.82
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS5.92
BVpS3.96
TBVpS3.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.99%
ROE -42.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.89%
FCFM N/A
ROA(3y)-12.67%
ROA(5y)-11.54%
ROE(3y)-72.98%
ROE(5y)-56.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.08%
GM growth 5Y-0.24%
F-Score5
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0.99
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 275.02%
Cap/Sales 6.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.87
Quick Ratio 2.86
Altman-Z 1.36
F-Score5
WACC8.96%
ROIC/WACCN/A
Cap/Depr(3y)135.24%
Cap/Depr(5y)139.85%
Cap/Sales(3y)4.04%
Cap/Sales(5y)3.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%255.56%
EPS Next Y15.47%
EPS Next 2Y1.66%
EPS Next 3Y12.11%
EPS Next 5Y25.75%
Revenue 1Y (TTM)16.05%
Revenue growth 3Y-4.54%
Revenue growth 5Y-8.88%
Sales Q2Q%100.67%
Revenue Next Year38.9%
Revenue Next 2Y22.13%
Revenue Next 3Y25.89%
Revenue Next 5Y29.04%
EBIT growth 1Y26.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.83%
EBIT Next 3Y18.2%
EBIT Next 5YN/A
FCF growth 1Y40.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.45%
OCF growth 3YN/A
OCF growth 5YN/A